REFERENCES
- Rohmer J, Couteau-Chardon A, Trichereau J, Panel K, Gesquiere C,
Abdelali RB, et al. Epidemiology, clinical picture and long-term
outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia:
data from 151 patients. Am J Hematol. 28 juill 2020
- Legrand F, Renneville A, Macintyre E, Mastrilli S, Ackermann F,
Cayuela JM, et al. The Spectrum of FIP1L1-PDGFRA-Associated Chronic
Eosinophilic Leukemia: New Insights Based on a Survey of 44 Cases.
Medicine (Baltimore). 2013;(5):e1-e9
- Qu SQ, Qin TJ, Xu ZF et al. Long term outcomes of Imatinib in patients
with FIP1L1/PDGFRA associated chronic eosinophilic leukemia:
experience of a single center in China. Oncotarget. 2016; è (22):
33236.
- Helbig G, Soja A, Swiderska A, Hus M, Kyrcz-Krzemień S. Imatinib
discontinuation for hypereosinophilic syndrome harboring the
FIP1L1-PDGFRA transcript. Leuk Lymphoma. 2016; 57 (3): 708-710.
- Klion AD, Robyn J, Maric I et al. relapse following discontiniuation
of Imatinib mesylate thérapye for FIP1L1/PDGFRA-positive chronic
eosinophilic leukemia: implication for optimal dosing. Boold 2007; 110
(10): 3552-3556.
- Metzgeroth G, Schwaab J, Naumann N, Jawhar M, Haferlach T, Fabarius A,
et al. Treatment-free remission in FIP1L1-PDGFRA-positive
myeloid/lymphoid neoplasms with eosinophilia after imatinib
discontinuation. Blood Adv. 2020;4(3):440‑3.